{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:31:07Z","timestamp":1784543467070,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.semarthrit.2021.04.013","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T12:18:02Z","timestamp":1619612282000},"page":"839-844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The role of vascular inflammation markers in deficiency of adenosine deaminase 2"],"prefix":"10.1016","volume":"51","author":[{"given":"Ummusen","family":"Kaya Akca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdal","family":"Sag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muserref","family":"Kasap Cuceoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelda","family":"Bilginer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2021.04.013_bib0001","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fped.2018.00282","article-title":"Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2","volume":"6","author":"Lee","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.semarthrit.2021.04.013_bib0002","series-title":"GeneReviews\u00ae[Internet]","article-title":"Adenosine deaminase 2 deficiency","author":"Aksentijevich","year":"2019"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.04.013_bib0003","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamadermatol.2015.1635","article-title":"Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa","volume":"151","author":"Santiago","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.04.013_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neurad.2018.05.002","article-title":"Deficiency of adenosine deaminase 2; special focus on central nervous system imaging","volume":"46","author":"Bulut","year":"2019","journal-title":"J Neuroradiol"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.04.013_bib0005","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1307361","article-title":"Early-onset stroke and vasculopathy associated with mutations in ADA2","volume":"370","author":"Zhou","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.04.013_bib0006","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10875-018-0487-x","article-title":"Novel mutation in CECR1 leads to deficiency of ADA2 with associated neutropenia","volume":"38","author":"Cipe","year":"2018","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3899\/jrheum.181384","article-title":"A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2","volume":"47","author":"\u00d6zen","year":"2020","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0008","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-016-0111-7","article-title":"Monogenic polyarteritis: the lesson of ADA2 deficiency","volume":"14","author":"Caorsi","year":"2016","journal-title":"Pediatr Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.04.013_bib0009","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1136\/annrheumdis-2016-210802","article-title":"ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study","volume":"76","author":"Caorsi","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.04.013_bib0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood.2019001251","article-title":"NETing the mechanism of inflammation in DADA2","volume":"134","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0011","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12969-017-0193-x","article-title":"Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation","volume":"15","author":"Skrabl-Baumgartner","year":"2017","journal-title":"Pediatr Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.04.013_bib0012","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3899\/jrheum.180045","article-title":"Variable clinical phenotypes and relation of interferon signature with disease activity in ADA2 deficiency","volume":"46","author":"Insalaco","year":"2019","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.04.013_bib0013","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00296-019-04364-y","article-title":"Cytokine profiling in anti neutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional cohort study","volume":"39","author":"Hoffmann","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2021.04.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/603750","article-title":"Increased levels of soluble ST2 in patients with active newly diagnosed ANCA-associated vasculitis","volume":"2015","author":"Hladinova","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/BOR.0000000000000009","article-title":"Biomarkers in vasculitis","volume":"26","author":"Monach","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.04.013_bib0016","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/01.STR.0000153795.38388.72","article-title":"Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor-\u03b1 in a rodent experimental stroke model","volume":"36","author":"Ardelt","year":"2005","journal-title":"Stroke"},{"issue":"1-2","key":"10.1016\/j.semarthrit.2021.04.013_bib0017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vph.2011.12.003","article-title":"Biomarkers of inflammation and endothelial function: the holy grail of experimental and clinical medicine?","volume":"56","author":"Biasucci","year":"2012","journal-title":"Vascul Pharmacol"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.04.013_bib0018","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/ndt\/gfh487","article-title":"Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis","volume":"19","author":"Tam","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.04.013_bib0019","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10875-018-0525-8","article-title":"Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment","volume":"38","author":"Meyts","year":"2018","journal-title":"J Clin Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.04.013_bib0020","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch\u2013Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria","volume":"69","author":"Ozen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.04.013_bib0021","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1097\/MPH.0000000000000805","article-title":"Refractory pure red cell aplasia manifesting as deficiency of adenosine deaminase 2","volume":"39","author":"Hashem","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.04.013_bib0022","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","article-title":"Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)","volume":"145","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/meth.1999.0837","article-title":"Interleukin-18","volume":"19","author":"Dinarello","year":"1999","journal-title":"Methods"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.04.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140036","article-title":"In-Depth, Label-Free analysis of the erythrocyte cytoplasmic proteome in Diamond Blackfan Anemia identifies a unique inflammatory signature","volume":"10","author":"Pesciotta","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2021.04.013_bib0025","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.2741\/e178","article-title":"Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker","volume":"2","author":"Yamagishi","year":"2010","journal-title":"Front Biosci (Elite Ed)"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.04.013_bib0026","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.metabol.2006.05.007","article-title":"Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects","volume":"55","author":"Yamagishi","year":"2006","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0027","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mvr.2007.09.004","article-title":"Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes","volume":"76","author":"Nakamura","year":"2008","journal-title":"Microvasc Res"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.04.013_bib0028","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mus.20039","article-title":"Receptor for advanced glycation endproduct (RAGE)\u2013mediated nuclear factor-\u03baB activation in vasculitic neuropathy","volume":"29","author":"Haslbeck","year":"2004","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.04.013_bib0029","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/brb3.176","article-title":"Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies","volume":"3","author":"Juranek","year":"2013","journal-title":"Brain Behav"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2004.00259.x","article-title":"Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia","volume":"73","author":"Hara","year":"2004","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.04.013_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-020-00944-1","article-title":"The many faces of a monogenic autoinflammatory disease: adenosine deaminase 2 deficiency","volume":"22","author":"Kendall","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0032","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/tpj.2016.84","article-title":"Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy","volume":"18","author":"Bank","year":"2018","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.04.013_bib0033","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MOH.0000000000000361","article-title":"The angiopoietins and Tie2 in vascular inflammation","volume":"24","author":"Parikh","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.04.013_bib0034","first-page":"397","article-title":"Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cells","volume":"12","author":"Rodewald","year":"1996","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.04.013_bib0035","doi-asserted-by":"crossref","first-page":"e82088","DOI":"10.1371\/journal.pone.0082088","article-title":"Tie2 signaling cooperates with TNF to promote the pro-inflammatory activation of human macrophages independently of macrophage functional phenotype","volume":"9","author":"Garc\u00eda","year":"2014","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.04.013_bib0036","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41431-018-0130-6","article-title":"A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience","volume":"26","author":"Rama","year":"2018","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.04.013_bib0037","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJMoa1307362","article-title":"Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy","volume":"370","author":"Navon Elkan","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2021.04.013_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.01.018","article-title":"Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation","author":"Nihira","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221000688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221000688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:07:19Z","timestamp":1758733639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0049017221000688"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.04.013","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of vascular inflammation markers in deficiency of adenosine deaminase 2","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}